Open AccessTreatment of influenza A (H1N1) virus infection with ribavirin aerosol
Author(s) -
Samuel Z. Wilson,
Brian E. Gilbert,
John Quarles,
Ver Knight,
H W McClung,
Rebecca V. Moore,
R B Couch
Publication year - 1984
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.26.2.200
Subject(s) - ribavirin , virus , medicine , viral shedding , influenza a virus , virology , gastroenterology , immunology , hepatitis c virus
In a randomized, controlled study of ribavirin aerosol treatment of influenza A(H1N1) virus infection among college students, treated patients had a significantly shorter duration of fever than control patients. There was a trend of more rapid recovery in treated patients. Virus shedding was similar in treated and control patients, declining gradually from a 50% tissue culture infective dose of 3.5 log10 per ml at admission to 1.8 log10 per ml at 53 h after admission. There was no local or systemic intolerance and no hematological or biochemical abnormalities associated with ribavirin treatment.